Search

everythinglearnresearchcommunity

for

Search:↓

DHEA supplementation may improve quality of life, neuropsychological functions, and sexual satisfaction in individuals with adrenal insufficiency, but more research is needed to confirm its safety and effectiveness.

The document concludes that managing PCOS involves lifestyle changes, medication, and monitoring for associated health risks.

Women with Polycystic Ovary Syndrome (PCOS) have a higher risk of developing type 2 diabetes due to insulin resistance.

Natural products may help treat skin inflammation from abnormal adrenal hormones.

Finasteride effectively reduces hair growth in women with idiopathic hirsutism, but requires careful contraception during treatment.

Testosterone therapy is generally safe for transmen, improves sexual function, and has manageable health risks with proper monitoring.

Acne in adult women may occur alone or with signs of high male hormones.

PCOS is a common hormonal disorder in women, treated with lifestyle changes and medications like hormonal contraceptives and metformin.

Medications for glucose metabolism and weight control, combined therapy options, and herbal medicines may help regulate menstrual cycle in adolescents with PCOS.

Transgender women can develop feminine traits and improve their quality of life through hormone therapy and surgery, but results vary and access to surgery can be limited.

New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.

Women with acne and irregular periods had higher active testosterone levels, which could suggest the usefulness of antiandrogen treatment.

DHEA did not improve sexual function, well-being, or menopausal symptoms in postmenopausal women with low libido but caused side effects like acne and increased facial hair.

The document concludes that gender-affirming treatments are essential for transgender individuals and outlines safe hormone therapy practices.

Hormonal changes and psychological issues can cause sexual dysfunction in postmenopausal women. Behavioral therapy is recommended first, with hormone replacement helping some symptoms but not libido. Testosterone can improve libido, but its effects on overall sexual function are unclear. Emotional and relationship issues should be addressed before using medication, and the benefits and risks of testosterone supplementation should be considered.

For women with moderate to severe unwanted hair growth or acne, birth control pills are the first choice, with other medications like cyproterone, spironolactone, flutamide, or finasteride as alternatives, and permanent hair removal should be done with electrolysis or laser.

Women with moderate body hair have higher levels of certain hormones and may benefit from treatment that increases sex hormone-binding protein.

Metformin and rosiglitazone both improved insulin use and hormonal symptoms in women with PCOS.

Hair loss in men and women is linked to high stress hormone levels and other hormonal imbalances, suggesting treatments should be customized to each person's hormones.

Treatment of acromegaly can improve women's reproductive health issues caused by hormonal imbalances or tumors.

Acne lesions start with changes in hair follicles and increase in inflammation, suggesting a cycle that could affect treatment strategies.

Women with PCOS have a higher risk of metabolic syndrome and need lifestyle changes and treatment.

Non-classic congenital adrenal hyperplasia (NCCAH) can mimic PCOS and requires genetic testing for proper diagnosis and treatment.

The document concludes that insulin resistance is key in PCOS development and early treatment is crucial to prevent complications.

Women with AGA have more androstenedione and dihydrotestosterone, less copper and zinc; copper imbalance affects AGA; treatment improves hormones and minerals.

The bulletin provides guidelines for diagnosing and managing PCOS, suggesting weight loss, hormonal contraceptives, and diabetes screening, with clomiphene for infertility and various treatments for excess hair.

Androgens significantly affect female hair loss, and hormonal treatments may help.

Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.

The paper suggests that a decrease in estrogen receptor activity may cause sexual dysfunction syndromes and proposes hormonal treatments.

The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.